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The target of rapamycin (TOR) pathway is a major
nutrient-sensing pathway that, when genetically
downregulated, increases life span in evolutionarily
diverse organisms including mammals. The central
component of this pathway, TOR kinase, is the target
of the inhibitory drug rapamycin, a highly specific
and well-described drug approved for human use.
We show here that feeding rapamycin to adult
Drosophila produces the life span extension seen in
some TOR mutants. Increase in life span by rapamy-
cin was associated with increased resistance to both
starvation and paraquat. Analysis of the underlying
mechanisms revealed that rapamycin increased
longevity specifically through the TORC1 branch of
the TOR pathway, through alterations to both au-
tophagy and translation. Rapamycin could increase
life span of weak insulin/Igf signaling (IIS) pathway
mutants and of flies with life span maximized by die-
tary restriction, indicating additional mechanisms.
INTRODUCTION
The TOR (target of rapamycin) pathway is a highly conserved
nutrient-sensing pathway that functions in such evolutionarily
distinct organisms as yeast and mammals to regulate growth
and metabolism in response to growth factors, amino acids,
various stresses, and changes in cellular energy status. It has
also been implicated in the control of protein translation and ribo-
some biogenesis, upregulation of which is required for growth
(for detailed review, see Wullschleger et al., 2006). More recently,
the TOR pathway has emerged as an important modulator of
aging, an effect firmly established in several invertebrate models
(Kaeberlein and Kennedy, 2008).
The central component of the TOR pathway is TOR kinase,
which participates in two different multiprotein complexes:
TORC1 and TORC2. TORC1 regulates translation and growth
through phosphorylation of two key downstream effectors, S6K
and 4E-BP. Thus, under favorable conditions, such as an amino
acid-rich diet, when TORC1 is active, phosphorylated S6K func-
tions as a positive mediator of the TOR pathway by promotingCcellular and organismal growth, and additionally by altering
metabolism (Montagne et al., 1999; Um et al., 2006). Accordingly,
S6K-deficient animals are smaller, and their metabolism repli-
cates conditions of low-calorie diet, although the exact mecha-
nisms responsible are not completely understood (Um et al.,
2006). TORC1-dependent phosphorylation of 4E-BP disrupts
its association with the translation initiation factor 4E (eIF4E),
allowing the latter to promote cap-dependent translation. All
nuclear-encoded eukaryotic mRNAs possess a cap structure
consisting of 50 7-methylguanosine, which allows them to be
recruited to the ribosome and translated in a cap-dependent
manner when conditions are favorable (Sonenberg and Hinne-
busch, 2009). However, under stress, such as lack of nutrients
or growth factors, and in hypoxia, cap-independent translation
increases (Sonenberg and Hinnebusch, 2009), allowing a switch
to synthesis of other proteins, such as growth factors and heat
shock proteins (Baird et al., 2006), which enables the cell to
respond to stress and to survive, rather than to initiate apoptosis.
Under starvation, TORC1 additionally promotes autophagy,
a critical process for supplying starving cells with bioenergetic
components (Lum et al., 2005). During autophagy, cytosolic con-
tents targeted for degradation, including proteins, lipids, nucleic
acid, and carbohydrates, are enclosed by a double-membrane
structure, the autophagosome, which ultimately fuses with a
lysosome for degradation of its cargo (Klionsky, 2007). This not
only provides the cell with nutrients and energy but also removes
damaged cellular components and thus has an important cyto-
protective function.
In contrast to the plethora of known TORC1 functions, the
TORC2 complex seems to be mainly involved in actin organiza-
tion and, additionally, to upregulate the IIS pathway by activating
phosphorylation of Akt, the main kinase in the IIS pathway
(Wullschleger et al., 2006). Akt can then phosphorylate and inac-
tivate TSC2, a TOR pathway suppressor. Contrary to the positive
effects of TORC2 on the IIS pathway, S6K, a downstream com-
ponent of TORC1, inhibits IIS by negatively regulating the
insulin receptor substrate (IRS) at the level of transcription,
degradation and phosphorylation (Um et al., 2006; Wullschleger
et al., 2006). Thus, there is a complex cross-wiring between the
two signaling pathways, the outcome of which may depend on
cell type and on the intensity and duration of the signal (Sarbas-
sov et al., 2006).
TOR kinase is inhibited by rapamycin, a natural macrolide
compound isolated from bacteria, analogs of which areell Metabolism 11, 35–46, January 6, 2010 ª2010 Elsevier Inc. 35
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cancer therapy (Guertin and Sabatini, 2009; Hartford and Ratain,
2007). Rapamycin is the most specific TOR inhibitor known and
inhibits through association with the intracellular protein
FKBP12, which then binds to the FKBP12-rapamycin-binding
(FRB) domain of TOR, inhibiting TORC1 activity. Although rapa-
mycin does not bind the catalytic domain of TOR, it reduces
phosphorylation of two downstream TORC1 targets, S6K and
4E-BP. Rapamycin is generally accepted as an inhibitor of
cap-dependent translation, and its capacity to upregulate au-
tophagy and cap-independent translation is well described
(Grolleau et al., 2002; Ravikumar et al., 2004).
Inhibition of TOR activity can delay the aging process, as evi-
denced by increased life span in yeast (Kaeberlein et al., 2007),
worms (Hansen et al., 2007; Vellai et al., 2003), flies (Kapahi
et al., 2004; Luong et al., 2006), and mice (Selman et al., 2009)
with mutations in TOR pathway components. For instance, in
yeast, both chronological and replicative life span are extended
in the tor1D mutant (Kaeberlein et al., 2007) and worms
bearing mutations in genes encoding the worm homolog of
TOR (let-363) and S6K (rsks-1), and components of the transla-
tional machinery, such as ribosomal proteins and translation
initiation factors, live longer (Hansen et al., 2007; Kaeberlein
and Kennedy, 2008; Syntichaki et al., 2007). Flies mutant for
TOR, and with overexpression of dominant-negative forms of
S6K or TSC1 or TSC2, which encode negative regulators of
TOR, are all long lived (Kapahi et al., 2004; Luong et al., 2006).
Recently, it has been shown that genetic deletion of S6K1 in
mice extends life span (Selman et al., 2009). Taken together,
these data demonstrate an evolutionarily conserved role for
TOR in determination of life span.
The TOR pathway may also play an important role in dietary
restriction (DR), a key antiaging intervention in which reduced
food intake without malnutrition results in extended life span
in most organisms so far tested (Bishop and Guarente, 2007;
Mair and Dillin, 2008), including rhesus monkeys (Colman
et al., 2009). Although the mechanisms underlying DR are not
entirely understood, DR does not further increase life span
when TOR signaling is already reduced in yeast, worms, or flies,
suggesting that common mechanisms may mediate both of
these antiaging interventions (Grandison et al., 2009). This may
be related to the importance of amino acids for both of these
longevity responses (Mair et al., 2005; Sancak and Sabatini,
2009).
To explore mechanisms underlying the role of the TOR path-
way during aging, we have taken a pharmacological approach
using Drosophila, which provides an ideal context for in vivo
studies of TOR signaling and aging, because components of
this pathway show strong evolutionary conservation from flies
to mammals, and Drosophila TOR pathway mutants are well-
described.
We administered rapamycin to adult flies by feeding and
found that it robustly extended life span, exclusively through
the TORC1 branch of the pathway. Rapamycin-mediated life
span extension was not associated with alterations in either IIS
or AMP-activated protein kinase (AMPK) activity but was
blocked by alterations to both autophagy and translation. In
addition, rapamycin extended life span beyond the maximum
seen with DR and lessened the reduction in life span with full36 Cell Metabolism 11, 35–46, January 6, 2010 ª2010 Elsevier Inc.feeding, suggesting that rapamycin treatment captures some
of the mechanisms by which DR extends life span but also
acts through additional mechanisms. Moreover, our results
showed that a weak, but not a strong, IIS mutant could extend
life span of flies with life span maximized through rapamycin
treatment, indicating additional mechanisms. Thus, rapamycin
acts at a level in the TOR pathway that captures multiple down-
stream target processes to extend life span.
RESULTS
Rapamycin Treatment Efficiently Reduces
Phosphorylation of S6K In Vivo
To determine if rapamycin inhibits TOR activity in vivo in
Drosophila, we fed rapamycin to flies. To avoid developmental
effects, flies were reared on normal food and then given food
supplemented with rapamycin from early adulthood (see the
Experimental Procedures and the Supplemental Information
available online for details of fly stocks and food media). By using
a blue-dye feeding assay combined with feeding observations
(Wong et al., 2009), we found no significant effect of rapamycin
on feeding behavior or on the amount of food consumed
(Figure S1). The concentration of rapamycin in flies fed on
200 mM food, measured by mass spectrometry, was 3.3 ±
0.2 ng/mg wet weight, comparable to the effective dose admin-
istered to mice for life span analysis (Harrison et al., 2009).
We measured phosphorylation of S6K, a well-described
downstream target of TORC1, as an indicator of rapamycin effi-
cacy, by western blot analysis using a phospho-Thr398-depen-
dent S6K antibody. We observed a significant dose-dependent
reduction in phospho-T398-S6K levels after rapamycin treat-
ment for 1–3 days, confirming that rapamycin reduced TOR
signaling in vivo (Figure 1A). To determine bioavailability of rapa-
mycin throughout the fly, we measured S6K phosphorylation in
different regions of the fly body. Phospho-T398-S6K levels
were decreased to similar levels in heads, thoraces, and abdo-
mens (Figure 1B), suggesting that TOR signaling is ubiquitously
downregulated in adult flies upon rapamycin treatment.
Rapamycin Extends Life Span, Increases Stress
Resistance, Reduces Fecundity, and Increases
Lipid Levels
We next investigated the effects of rapamycin on life span when
administered at different concentrations. Whereas 1 mM rapamy-
cin had no effect, significant life span extension occurred at 50,
200, and 400 mM in repeated experiments (Figures 2A and 2B),
with no significant differences in survival between flies exposed
to the three effective concentrations. In subsequent experi-
ments, we used 200 mM rapamycin, which produced the largest
increase in median life span. To test the generality of the effect of
rapamycin on life span, we examined two other, frequently used
laboratory strains, w1118 and yw, and observed significant
increases in median life span in both (Figures S2A and S2B).
Rapamycin also increased life span of male flies, less so than
that of females (Figure 2C). This sexual dimorphism is also
observed in mice, where rapamycin-mediated life span extension
is smaller in males than in females (Harrison et al., 2009), and only
female S6K1 mutant mice are long lived (Selman et al., 2009).
Furthermore, we found that removal of the cytoplasmic
whole fly
phospho-T398-S6K
abdomen thorax head
2000 400
1 day 3 day 5 day 12 day 
rapamycin (µM)
2000 2000 2000 2000rapamycin (µM)
total S6K
total S6K
A
B
phospho-T398-S6K
2000 400 2000 400 2000 400
0.60 0.431.00 1.00 0.45 0.25 1.00 0.36 0.12 1.00 0.42 0.13relative band intensity
1.00 0.20 1.00 0.33 1.00 0.24 1.00 0.25relative band intensity
Figure 1. Rapamycin Treatment of Adult
Drosophila Downregulates TOR Activity
(A) Western blot analysis of phospho-S6K on
whole-fly protein extracts. Flies were sampled
after 1, 3, 5, or 12 days of rapamycin treatment
at concentrations of 200 or 400 mM. A dose-
dependent reduction in phospho-T398-S6K levels
was observed and the degree of inhibition
increased with longer treatment time. For all
western blots, relative band intensity was esti-
mated using Image J.
(B) Western blot analysis of phospho-S6K in
different body parts of wDah flies. Flies were
maintained with or without 200 mM rapamycin
for 2 weeks prior to preparation of protein
extracts from heads, thoraces, and abdominal
segments. Rapamycin was found to efficiently
reduce levels of phospho-T398-S6K in all fly
body parts.
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Life Span Extension by Rapamycin in Drosophilaendosymbiont Wolbachia, which can modulate life span of some
Drosophila mutants (Ikeya et al., 2009; Toivonen et al., 2007), did
not affect extension of life span by rapamycin (Figures S2C and
S2D). Thus, rapamycin consistently extended fly life span in
diverse genetic and cytoplasmic backgrounds and in both sexes.
Rapamycin also reduced female fecundity in a dose-depen-
dent manner, with a mild decrease at 50 mM and much more
severe effects at 200 and 400 mM (Figure 2D and Figure S2F).
However, since the three concentrations of rapamycin had sim-
ilar effects on life span, there was no simple correlation between
fecundity and longevity, arguing against a causal connection
between them. Moreover, rapamycin extended the life span of
sterile females carrying the ovoD mutation (Figure S2E), further
confirming that extension of life span by rapamycin cannot be
simply explained by reduced fecundity.
Interventions that extend fly life span are often associated with
resistance to various stresses (Broughton et al., 2005; Clancy
et al., 2001). We therefore tested rapamycin-treated flies for
survival under starvation and treatment with paraquat, an oxida-
tive stress inducer. Flies were pretreated with rapamycin for
2 weeks and then transferred to either agar-only food for starva-
tion assays or to food supplemented with 20 mM paraquat.
Pretreatment with rapamycin significantly increased survival
under both starvation and paraquat treatment (Figures 2E
and 2F). Furthermore, pretreatment with rapamycin increased
survival after paraquat injection, ruling out any effect of rapamy-
cin on feeding behavior as an explanation (Figure S2G).
The TOR pathway is a key controller of cellular metabolism,
by coordinating nutrient supply and available energy withCell Metabolism 11, 35–cellular demands for protein synthesis
and growth. Consequently, it affects fat
metabolism and energy reserves of
triglycerides, which may enable animals
to survive for longer in periods of starva-
tion (Wullschleger et al., 2006). We there-
fore measured triacylglyceride (TAG)
levels in flies treated with rapamycin
and, in agreement with others (Teleman
et al., 2005), we found that rapamycintreatment resulted in significantly elevated TAG levels
(Figure 2G).
Rapamycin Treatment Mediates Life Span Extension
Independently of Effects on IIS and AMPK
Rapamycin is generally thought to be a specific inhibitor of
TORC1, whereas TORC2 is considered to be rapamycin insensi-
tive (Wullschleger et al., 2006). However, in some cell lines, pro-
longed rapamycin treatment can also inhibit TORC2 activity
(Sarbassov et al., 2006). Because we administered rapamycin
from early adulthood until death, and also because TORC2 has
been implicated in aging in worms (Soukas et al., 2009), we
determined whether TORC2 activity was reduced by rapamycin.
TORC2 phosphorylates and activates AKT kinase at Ser505.
Western blot analysis of whole-fly protein extracts did not reveal
a measurable effect of rapamycin on TORC2-specific phosphor-
ylation of Akt at Ser505 (Figure 3A). We found no effect of rapa-
mycin on phosphorylation of GSK3a/b at the Ser21/9 site, an
output of IIS/Akt activity (Figure 3B). Taken together, these
data suggest that neither TORC2 nor IIS was affected by rapa-
mycin treatment.
AMPK is a cellular energy sensor that is activated when the
AMP/ATP ratio is high. Subsequently, activated AMPK inhibits
TOR signaling by activating phosphorylation of the TOR sup-
pressor TSC2, thereby adjusting the cell’s metabolic program
to energy status (Towler and Hardie, 2007). Conversely, S6K
regulates AMPK by changing the AMP/ATP ratio (Aguilar et al.,
2007). Since S6K activity was downregulated upon rapamycin
administration, we examined the phosphorylation status of the46, January 6, 2010 ª2010 Elsevier Inc. 37
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Figure 2. Effects of Rapamycin on Life Span and Fecundity in Various Standard Laboratory Strains
(A) Rapamycin treatment extends the life span of wDah females. Compared to flies on control food (0 mM rapamycin), flies on 50 and 200 mM rapamycin food have
increased median life spans (p = 0.0005 and p < 0.0001, log-rank test).
(B) Rapamycin treatment at 50, 200, and 400 mM extends the life span of wDah females (p = 0.0428, p < 0.0001, p = 0.0013, log-rank test compared to control).
(C) Rapamycin extends life span in wDah males (p = 0.0241, log-rank test).
(D) Reduced fecundity of females on 50, 200, and 400 mM rapamycin food. Data are given as mean number of eggs laid per female per day ± SEM. T test p values
between egg laying under different conditions are p < 0.005. For each time point and each condition, eggs from ten vials containing ten flies per vial were counted.
(E) Rapamycin enhances starvation resistance (p < 0.0001, log-rank test). For all stress assays,wDah females were pretreated for 2 weeks with 200 mM rapamycin,
and initial population was 100 flies per condition.
(F) Rapamycin pretreated wDah females have improved survival on paraquat (p < 0.0001, log-rank test).
(G) Rapamycin treatment increases TAG levels. TAG levels in wDah flies were measured after 14 days of rapamycin treatment from heads and thoraces of five
females. Twelve samples were measured per treatment. Data are shown as mean ± SEM. * indicates statistical significance of difference between untreated
and rapamycin-treated flies (t test, p < 0.05).
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Figure 3. Rapamycin Treatment Does Not Affect IIS Signaling or
AMPK Activity
Western blot analyses of downstream components of IIS signaling and of
AMPK phosphorylation. Protein extracts were made from whole flies after
14 days of rapamycin treatment. No changes in the levels of phospho-
Ser505-Akt (A), phospho-Ser21/S9-GSK3 (B), or phospho-T172-AMPK (C)
were observed. The presence of two bands for AKT is due to two isoforms
present in flies (A). GSK3 has several isoforms in flies, and two of them are
detected in this blot (B).
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Life Span Extension by Rapamycin in Drosophilacatalytic subunit of AMPK at the Thr172 site, to determine if
rapamycin treatment activated AMPK. We observed no changes
in AMPK phosphorylation after prolonged rapamycin treatment
(Figure 3C), excluding AMPK activation as a possible effector
of rapamycin-mediated effects on longevity.Extension of Life Span by Rapamycin Is Mediated
by Several Downstream Targets of TORC1
Inhibition of TOR signaling has pleiotropic effects on cell
physiology, including activation of autophagy (Klionsky, 2007),
decreased cap-dependent translation, and increased cap-inde-
pendent translation (Sonenberg and Hinnebusch, 2009). These
changes could all potentially contribute to rapamycin-mediated
life span extension. We first examined the effects of rapamycin
on translation and autophagy. Rapamycin treatment produced
a significant decrease in the incorporation of 35S-methionine,
suggesting that rapamycin treatment inhibited translation (Fig-
ure 4A). There was also a significant increase in the number of
LysoTracker-stained lysosomes and autolysosomes after rapa-Cmycin treatment, indicative of autophagy induction (Figures 4B
and 4C). Rapamycin treatment thus affected physiological
processes downstream of TORC1.
We next determined the processes that mediated life span
extension by rapamycin. S6K mediates the downstream effects
of TOR signaling on translation initiation, and downregulation of
protein translation has been shown to increase life span in
worms (Hansen et al., 2007; Kaeberlein and Kennedy, 2008;
Syntichaki et al., 2007). We therefore examined the effects of
rapamycin on flies ubiquitously overexpressing a constitutively
active form of S6K (Barcelo and Stewart, 2002), and found that
rapamycin had no significant effects on life span (Figure 5A), sug-
gesting that rapamycin extended life span by downregulation of
S6K activity. Downregulation of TOR signaling leads to 4E-BP
activation, resulting in inhibition of cap-dependent translation
(Sonenberg and Hinnebusch, 2009). We therefore administered
rapamycin to 4E-BP null mutant flies (Tettweiler et al., 2005)
and found that it did not significantly extend their life span
(Figure 5C), suggesting that 4E-BP also mediates extension of
life span by rapamycin.
Rapamycin has been shown to upregulate autophagy, an
evolutionarily conserved cellular process that removes damaged
proteins and entire organelles from cells and that may play a role
in life span extension (Diaz-Troya et al., 2008; Ravikumar et al.,
2004; Simonsen et al., 2008; Toth et al., 2008). We therefore
determined whether upregulation of autophagy mediated exten-
sion of life span by rapamycin. ATG5 is required for formation of
autophagosomes and is specific and essential for autophagy
(Reggiori and Klionsky, 2005). Ubiquitous double-stranded
RNA interference against Atg5, which inhibits autophagy induc-
tion (Ren et al., 2009; Scott et al., 2004), resulted in an approxi-
mate 2-fold reduction in Atg5 expression as determined by
QPCR (Figure S3) and completely abrogated the extension of
life span by rapamycin (Figure 5E), suggesting that upregulation
of autophagy mediates the life span extension.
Interestingly, all of the genetic models in which we manipu-
lated the activity of downstream targets of TORC1 were starva-
tion sensitive; flies overexpressing a constitutively active S6K,
4E-BP nulls, and flies with reduced expression of Atg5 were
more sensitive to starvation than their controls (Figures 5B, 5D,
and 5F). Although rapamycin treatment did not increase life
span in these flies, it did significantly increase their starvation
resistance (Figures 5B, 5D, and 5F), demonstrating that these
two traits can be uncoupled.
Rapamycin Treatment Can Further Extend Life Span
of Some Long-Lived IIS Mutants
Downregulation of IIS can extend life span in diverse organisms
(Piper et al., 2008). Because of the many potential interactions
between the TOR pathway and IIS, we investigated whether
rapamycin treatment could further increase the life span of
long-lived IIS mutants. Rapamycin treatment of flies heterozy-
gous for chico1, a null mutation in the gene encoding the
single Drosophila IRS homolog, extended life span beyond
that induced by rapamycin treatment of controls (Figure 6A).
However, rapamycin treatment of chico1 homozygotes, which
have more strongly reduced IIS and longer life span than hetero-
zygotes (Figure 6A), shortened life span to levels comparable
with non-rapamycin-treated controls (Figure 6A). Rapamycinell Metabolism 11, 35–46, January 6, 2010 ª2010 Elsevier Inc. 39
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Figure 4. Rapamycin Increases Autophagy
and Decreases Protein Translation
(A) Levels of 35S-methionine incorporation in
7-day-old flies normalized to total protein con-
tent (±SEM). Rapamycin significantly reduces
35S-methionine incorporation (**p = 0.0033,
Student’s t test).
(B) Significantly more autolysosomes and lyso-
somes in rapamycin-treated flies (***p < 0.0001,
Student’s t test). Average number of LysoTracker-
stained puncta in fly midguts isolated from
rapamycin pretreated or control flies is presented
(±SEM).
(C) Representative confocal fluorescence images
of fly midgut stained with LysoTracker Red.
Midgut of control flies (upper image) and rapamy-
cin pretreated flies (lower image) are shown. L indi-
cates lumen of the gut; scale bar is 10 mM.
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Life Span Extension by Rapamycin in Drosophilatreatment was biochemically effective in chico1 homozygotes,
because phosphorylation of S6K was similarly downregulated
by rapamycin (Figure S4). Rapamycin treatment of flies with
reduced levels of Drosophila insulin-like peptides (DILPs) due
to the partial ablation of the DILP-producing median neurosecre-
tory cells (mNSC) (Broughton et al., 2005) did not further increase
life span in these long-lived flies (Figure 6B). Taken together,
these data suggest that, when life span by rapamycin treatment
is maximized, weak downregulation of IIS, as in chico1 heterozy-
gotes, can further extend life span, showing that IIS extends life
span by mechanisms additional to those affected by rapamycin.
However, stronger downregulation of IIS, which alone extends
life span, can be deleterious in the presence of rapamycin,
through as-yet-unidentified mechanisms.
We also examined the effects of rapamycin treatment on
stress resistance in IIS mutants. Rapamycin treatment increased
survival under starvation (Figure 6C) and paraquat treatment
(Figure 6D) not only of chico1 heterozygotes but also mNSC-
ablated flies, despite not causing an effect on life span of the
mNSC-ablated flies. The effects of these two interventions on
life span can thus be uncoupled from their effects on resistance
to starvation and paraquat treatment.
Rapamycin Extends Life Span beyond the Maximum
Achieved by Dietary Restriction
The TOR pathway may play an important role in DR, because
the effects of DR are abrogated in TOR pathway mutant yeast,
worms, and flies (Bishop and Guarente, 2007; Mair and Dillin,
2008). We therefore examined whether DR affected the life
span of rapamycin-treated flies (Figure 7 and Figure S5). Rapa-
mycin significantly extended median and maximum life span at
all food concentrations tested (Figure 7), although the extension
was lowest at the food concentration that maximized life span40 Cell Metabolism 11, 35–46, January 6, 2010 ª2010 Elsevier Inc.of untreated controls. The highest food
concentration (2.0xY) shortened the life
span of rapamycin-treated flies by only
4% as opposed to 8% in controls,
a highly significant difference. Thus,
rapamycin slightly extended life span of
flies that had already been maximizedby DR and maintained life span in the presence of increased
food.
DISCUSSION
The most well-validated antiaging interventions involve two
major nutrient-sensing pathways: IIS and TOR. Although strong
alterations of either of these signaling pathways can cause
adverse effects, including embryonic lethality, cancer, and dia-
betes, milder downregulation can be beneficial for health and
longevity in all organisms so far tested (Piper et al., 2008). An
important consequence of using IIS or TOR manipulations as
antiaging interventions is that they can also delay the progres-
sion of numerous diseases associated with old age, for example,
cancer, neurodegeneration, cardiovascular disease, and dia-
betes (Bishop and Guarente, 2007; Piper et al., 2008). Hence,
clarifying the role of the TOR pathway in aging, as well as its rela-
tionship with IIS, could provide valuable insights for developing
treatments for age-related diseases.
The aim of this study was to determine if a pharmacological
intervention to reduce TOR signaling had antiaging effects in
Drosophila and to identify the underlying mechanisms. Rapamy-
cin was chosen because it is the most specific and best-studied
TOR kinase inhibitor available (Hartford and Ratain, 2007; Wulls-
chleger et al., 2006). Importantly, rapamycin analogs have
already been approved for human use as immunosuppressant
drugs and are currently under clinical trials for use as anticancer
agents (Guertin and Sabatini, 2009).
We administered rapamycin to adult Drosophila and demon-
strated a dose-dependent downregulation of TOR activity after
just 1 day of treatment by measuring the phosphorylation status
of the TORC1 target, S6K. TOR inhibition by rapamycin was ubiq-
uitous, since the levels of phosphorylated S6K were similarly
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Figure 5. Rapamycin-Mediated Life Span Extension Is Blocked by the Ubiquitous Overexpression of Constitutively Active S6K, the Absence
of 4E-BP, or Downregulation of Atg5
(A) Ubiquitous overexpression of a constitutively active form of S6K (UAS-S6Kconst.act.) by the daughterless-GAL4 (daGAL4) driver abolishes rapamycin-mediated
life span extension. Rapamycin increases median life span of wDah females (p < 0.0001, log-rank test), but not daGAL4 > UAS-S6Kconst.act$ (p = 0.1083, log-rank
test). On control 0 mM rapamycin food, overexpression of constitutively active S6K slightly decreases life span (p = 0.0463, log-rank test).
(B) Flies overexpressing constitutively active S6K are more sensitive to starvation compared to wDah control flies (p < 0.0001, log-rank test), and their starvation
resistance is improved by rapamycin (p < 0.0001, log-rank test).
(C) Rapamycin does not extend the life span of 4E-BP null mutant female flies (p = 0.4027, log-rank test) but does increase the life span of control yw flies
(p = 0.0033, log-rank test).
(D) 4E-BP null flies are sensitive to starvation compared to control flies (p < 0.0001, log-rank test), but rapamycin improves their starvation resistance (p < 0.0001,
log-rank test).
(E) Downregulation of autophagy abolishes rapamycin-mediated life span extension (p = 0.5383, log-rank test). Autophagy was downregulated by ubiquitous
overexpression of UAS-atg5-RNAi using daughterless-GAL4 (daGAL4 > UAS-atg5RNAi). Note that since the experiments were run in parallel, life span data
for wild-type controls are the same as in Figure 4A.
(F) Flies with ubiquitous overexpression of UAS-atg5-RNAi (daGAL4 > UAS-atg5RNAi) were more starvation sensitive compared to their controls (p < 0.0001, log-
rank test), and their starvation resistance was improved by rapamycin treatment (p < 0.0001, log-rank test). Note that these experiments were run in parallel to
those in Figures 4B and 4D, hence the life span data for controls are the same.
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Life Span Extension by Rapamycin in Drosophiladownregulated in all main segments of the fly body. Notably, we
found that continuous rapamycin treatment from early adulthood
resulted in a robust and reproducible extension of life span, inde-
pendent of the genetic and cytoplasmic background and sex of
the flies. Rapamycin treatment in yeast has been previously
shown to extend replicative (Medvedik et al., 2007) and chrono-
logical (Powers et al., 2006) life span, and a recent study has
shown that rapamycin also extends life span in mice when admin-
istered late in life (Harrison et al., 2009). These data, together with
our observation that rapamycin treatment also extends life spanCinDrosophila, suggest that the antiaging effects of rapamycin are
evolutionarily conserved.
Rapamycin treatment that increased life span also reduced
female fecundity. However, rapamycin also extended life span
of sterile ovoD females, strongly suggesting that reduced fertility
alone is not sufficient for rapamycin-mediated life span exten-
sion. In C. elegans also, downregulation of TOR, ribosomal
proteins, S6K, or elF genes decreases fecundity, and reduced
TOR signaling can extend life span in sterile mutants (Hansen
et al., 2007). In addition, a growing body of evidence suggestsell Metabolism 11, 35–46, January 6, 2010 ª2010 Elsevier Inc. 41
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Figure 6. Effect of Rapamycin Treatment on Long-Lived IIS Mutants
(A) Rapamycin extends the life span of long-lived chico1 heterozygotes, (p = 0.0005) but decreases the life span of chico1/chico1 homozygotes (p < 0.0001). On
control food, chico1 heterozygotes (p = 0.039) and chico1/chico1 nulls (p < 0.0001) have increased median life span compared to control wDah flies. Log-rank test
is used for analyses.
(B) Rapamycin does not extend the life span of mNSC-ablated flies. mNSCs were partially ablated by driving expression of the proapoptotic factor reaper
(UAS-rpr) in the mNSCs using the dilp2-GAL4 driver (d2GAL4). On control food, mNSC-ablated flies are long lived (p < 0.0001, log-rank test compared to control).
Log-rank test p values for rapamycin-treated versus nontreated flies of the same genotype are p < 0.0001 for wDah and p = 0.97 for d2GAL4 > UAS-rpr.
(C) Flies pretreated with 200 mM rapamycin survived longer under starvation conditions compared to untreated flies. Log-rank statistics for nontreated versus
rapamycin-pretreated flies for all genotypes are p < 0.0001. Compared to wild-type controls, both chico1 heterozygotes and mNSC-ablated flies were more resis-
tant to starvation without rapamycin pretreatment (p = 0.006 and p = 0.001, respectively, log-rank tests).
(D) Flies pretreated with 200 mM rapamycin survive longer when fed 20 mM paraquat. Log-rank statistics for nontreated versus rapamycin pretreated flies for
all genotypes are p < 0.0001. Compared to wild-type controls, mNSC-ablated flies were more resistant to paraquat ingestion without rapamycin pretreatment
(p < 0.0001, log-rank test).
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Life Span Extension by Rapamycin in Drosophilathat reduced fecundity and longevity can be uncoupled (Grandi-
son et al., 2009; Partridge et al., 2005).
TOR kinase is a central component of two protein complexes:
TORC1 and TORC2. Rapamycin is generally considered to be
a specific inhibitor of TORC1, although in some cell lines pro-
longed rapamycin treatment can also inhibit TORC2 activity
(Sarbassov et al., 2006). Rapamycin treatment significantly
reduced S6K phosphorylation, indicative of reduced TORC1
activity. However, we saw no change in phosphorylation of
Akt at a TORC2-specific phosphorylation site, suggesting that
TORC2 activity remained unchanged. Both TORC1 and TORC2
interact with components of the IIS pathway: the TORC2
complex phosphorylates and activates Akt kinase; conversely,
Akt phosphorylates and functionally inactivates the TOR path-
way suppressor protein TSC2. In addition, S6K inhibits IRS at
the level of translation, transcription, and phosphorylation,
thereby exerting a negative feedback loop on IIS (Um et al.,
2006; Wullschleger et al., 2006). Reduced IIS could therefore
contribute to extension of life span by rapamycin. However, we
did not detect any measurable change in GSK3a/b phosphoryla-
tion, an important downstream target of the IIS pathway, sug-
gesting that rapamycin treatment did not alter IIS output.42 Cell Metabolism 11, 35–46, January 6, 2010 ª2010 Elsevier Inc.We performed epistasis experiments to explore the functional
interactions between TOR and IIS in determination of life span.
When life span extension was maximized by rapamycin treat-
ment, the effects of IIS manipulation were dependent upon the
degree of IIS downregulation. Thus, while rapamycin treatment
further extended the life span of flies heterozygous for chico1,
a null mutation in the gene encoding the single Drosophila IRS
homolog, it shortened the life span of long-lived chico1 homozy-
gous flies. Rapamycin treatment was hence beneficial under
conditions of weaker IIS downregulation, possibly indicating
deleterious combined effect with stronger IIS downregulation.
Alternatively, extension of life span by rapamycin may require
chico1. Rapamycin did not alter the life span of flies in which
the insulin-producing mNSCs were partially ablated, possibly
because they are intermediate in degree of downregulation of
IIS. Since life span under rapamycin treatment was maximized,
the data from chico1 heterozygotes suggest that IIS and TOR
regulate life span, at least in part, by nonoverlapping mecha-
nisms. In C. elegans, life span extension of daf-2 (the worm
insulin receptor) mutants was not modified by RNAi against
TOR, suggesting that these two pathways may have overlapping
downstream targets (Hansen et al., 2007; Vellai et al., 2003). The
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Figure 7. Rapamycin Increases Life Span Irrespective of Food
Concentration
Rapamycin increases (A) median and (B) maximum life span across different
yeast concentrations in SYA food. Plotted are median life span values for
wDah against yeast concentration (0.13, 0.53, 1.03, 1.53, and 2.03 yeast)
in SYA food (black line) and on the same food concentrations but supple-
mented with 200 mM rapamycin (red line). Values on each of the curves repre-
sent median (A) or maximum (B) life span. Flies on 200 mM rapamycin food had
significantly increased life span at each yeast concentration (***p < 0.001, log-
rank test). For detailed statistical analyses and complete survival curves,
please see Figure S5. Maximum life span is defined as the median of the
last 10% survivorship.
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Life Span Extension by Rapamycin in DrosophilaIIS and TOR pathways may converge on a common downstream
target, with severe inhibition of the two pathways causing detri-
mental effects, for example, through the induction of apoptosis
(Talapatra and Thompson, 2001). An important downstream
effector of IIS-mediated life span extension is the Forkhead tran-
scription factor Foxo/DAF-16. However, in C. elegans, the life
span of daf-16 null mutants can be extended by reductions in
TOR signaling (Hansen et al., 2007), and, similarly, rapamycin
treatment can extend the life span of dFOXO null flies (C.S.
and L.P., unpublished data), suggesting that Foxo is not required
for rapamycin to extend life span.
Inhibition of TOR signaling via TORC1 has pleiotropic effects
on cell physiology, including activation of autophagy (Klionsky,
2007), downregulation of cap-dependent protein translation,Cand increased cap-independent translation (Sonenberg and Hin-
nebusch, 2009). All of these changes could potentially contribute
to the antiaging effects of rapamycin (Hansen et al., 2007, 2008;
Kaeberlein and Kennedy, 2008; Kapahi et al., 2004).
Elevated levels of autophagy are generally considered to be
beneficial for the prevention of aging, due to increased rates of
removal of damaged molecules and organelles (Klionsky,
2007). For example, upregulation of Atg8 in fly neurons extends
life span and is associated with decreased amounts of insoluble
ubiquinated and oxidatively damaged proteins (Simonsen et al.,
2008). Furthermore, downregulation of autophagy in C. elegans
shortens the life span of long-lived daf-2 mutant worms (Hansen
et al., 2008; Melendez et al., 2003), suggesting that autophagy is
required for the longevity effects of IIS mutants. However, higher
levels of autophagy alone do not appear to be sufficient for
increased life span, because daf-16 mutation blocks daf-2
longevity but does not reduce autophagy levels (Hansen et al.,
2008). Rapamycin induces autophagy, possibly by altering the
interaction of TORC1 with the autophagy proteins ATG13 and
ATG1 (Chang and Neufeld, 2009; Ravikumar et al., 2004). We
have shown that downregulation of autophagy blocks rapamy-
cin-mediated life span extension. Similar observations have
also been made for chronological life span in yeast (Alvers
et al., 2009). It is interesting to note that, although autophagy
seems to be an important contributor to longevity (Toth et al.,
2008), we did not observe shortening of life span upon reduced
expression of Atg5, which is in agreement with the previously
published observations (Ren et al., 2009).
Reduced protein translation can also have an antiaging effect.
Mutations in genes encoding ribosomal proteins, S6K, or trans-
lation initiation factors, which are involved in translation, can all
extend life span, in yeast, worms, and flies (Kaeberlein and Ken-
nedy, 2008). However, the precise mechanisms underlying
the antiaging effects of reduced translation remain elusive,
although several possible mechanisms have been proposed.
For example, energy saved by lowering translation may be rein-
vested in longevity-promoting processes; stresses imposed by
mutations in the translation machinery may result in cap-inde-
pendent translation and enrichment of different sets of proteins;
and improved protein homeostasis and better removal of
damage may allow for increased life span when translation is
altered (Kaeberlein and Kennedy, 2008). Rapamycin has been
shown to be a potent repressor of translation; both microarray
and proteomic analyses have demonstrated that rapamycin
significantly decreases translation of mRNA-encoding initiation
factors and ribosomal proteins (Grolleau et al., 2002; Guertin
et al., 2006). This effect on translation is mediated by the down-
stream targets of TORC1: S6K and 4E-BP (Fingar and Blenis,
2004; Wullschleger et al., 2006). We have shown that both
a constitutive upregulation of S6K activity and the absence of
4E-BP block rapamycin-mediated life span extension, suggest-
ing that downregulation of protein translation is an important
mediator of the effects of rapamycin on life span.
Thus, we have demonstrated that the positive in vivo effects of
rapamycin on life span are mediated by the TORC1-dependent
downstream processes, autophagy and protein translation.
However, it is not yet clear if the effects of autophagy and protein
translation are additive or if their combined effects are required
to extend life span. Downregulation of S6K alone is sufficientell Metabolism 11, 35–46, January 6, 2010 ª2010 Elsevier Inc. 43
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Life Span Extension by Rapamycin in Drosophilato extend life span in flies (Kapahi et al., 2004). However, S6K
activity modulates the activity of ATG1 kinase, an important
regulator of autophagy, which may thus be affected in addition
to translation (Lee et al., 2007). Thus, these processes may act
in concert to extend life span: autophagy may reduce cellular
damage and thereby provide cells with ATP and amino acids,
which can subsequently be used for cap-independent transla-
tion, stimulating the synthesis of proteins that are important for
stress resistance and, perhaps, longevity.
Interestingly, rapamycin treatment increased median and
maximum life span under DR. Life span of rapamycin-treated
flies was increased at all food concentrations, suggesting that
the effect of rapamycin on life span is at least partially indepen-
dent of the effects of DR. Therefore, rapamycin treatment
appears to capture all of the advantages of DR plus additional
benefits. Moreover, although rapamycin-treated flies still re-
sponded to DR, the DR response was less pronounced than in
controls, and, in particular, the rapamycin-treated flies were
more resistant to the effects of full feeding on mortality. The
mechanisms underlying DR and its interactions with the TOR
pathway are complex. For example, DR in C. elegans cannot
extend the life span of long-lived TOR RNAi worms, but it does
nevertheless extend the life span of mutants that have reduced
levels of S6K and ribosomal proteins (Bishop and Guarente,
2007; Hansen et al., 2007; Mair and Dillin, 2008). In Drosophila,
life span extension by DR cannot be increased further by ubiqui-
tous overexpression of the TOR suppressor, TSC2 (Kapahi et al.,
2004). However, our data demonstrate that rapamycin treatment
may involve additional longevity assurance pathways, because it
can increase life span beyond the maximum achieved by DR.
Interestingly, it was recently shown that 4E-BP extends life
span under DR by enhancing mitochondrial activity (Zid et al.,
2009), which may underlie part of the beneficial effects of
rapamycin.
In conclusion, we have shown that rapamycin treatment
delays aging, an effect more pronounced than DR and that could
further increase life span in combination with mild downregula-
tion of IIS, firmly demonstrating that rapamycin could be used
to study aging in flies. Future studies to investigate the effects
of rapamycin in disease model systems may reveal potential
common therapies for a wide range of age-related conditions.
EXPERIMENTAL PROCEDURES
Fly Stocks and Husbandry
The wild-type stock Dahomey was collected in 1970 in Dahomey (now Benin)
and has since been maintained in large population cages with overlapping
generations on a 12L:12D cycle at 25C. The white Dahomey (wDah) stock
was derived by incorporation of the w1118 mutation into the outbred Dahomey
background by backcrossing. All stocks were maintained and all experiments
were conducted at 25C on a 12 hr:12 hr light:dark cycle at constant humidity
using standard sugar/yeast/agar (SYA) media (Bass et al., 2007). For all exper-
iments, flies were reared at standard larval density, and eclosing adults were
collected over a 12 hr period. Flies were mated for 48 hr before sorting into
single sexes. Further details concerning fly mutants used can be found in
the Supplemental Experimental Procedures.
Rapamycin Treatment
Rapamycin (LC Laboratories) was dissolved in ethanol and added to SYA food
at appropriate concentrations (1, 50, 200, or 400 mM). For control food (0 mM),
ethanol alone was added.44 Cell Metabolism 11, 35–46, January 6, 2010 ª2010 Elsevier Inc.Stress Assays
For stress assays, flies were reared and housed as for life span experiments.
Flies were pretreated with rapamycin at 200 mM for 14 days and then trans-
ferred to food supplemented with 20 mM methylviologen (paraquat, from
Sigma) for oxidative stress assays, or to 1.5% agar for starvation assays.
Dietary Restriction
The DR protocol was described in detail in Bass et al. (Bass et al., 2007).
Statistical Analyses
Statistical analyses were performed using JMP software (version 4.0.5; SAS
Institute). Log-rank tests were performed for survival. Other data were tested
for normality using the Shapiro-Wilk W test on studentized residuals and,
where appropriate, log transformed. One-way analyses of variance (ANOVA)
and planned comparisons of means were made using Tukey-Kramer HSD
test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2009.11.010.
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